Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  RaySearch Laboratories AB (publ)    RAY B   SE0000135485

RAYSEARCH LABORATORIES AB (PUBL)

(RAY B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

RaySearch Laboratories : Interim report January 1 - June 30, 2020

share with twitter share with LinkedIn share with facebook
08/26/2020 | 02:46am EDT

"In the second quarter, net sales declined 14 percent due to lower license sales as a result of COVID-19. Operating loss totaled SEK -11 M (29), however adjusted for currency conversion effects the operating profit would have been SEK 16 M (25). Cash flow was strong and totaled SEK 66 M (4)", Johan Löf, CEO of RaySearch
 

SECOND QUARTER (APRIL-JUNE 2020)

· Order intake SEK 177.1 M (370.6)
· Net sales SEK 163.8 M (189.7)
· Operating loss SEK -10.9 M (28.8)
· Loss after tax SEK -9.2 M (21.8) and
loss per share before/after dilution SEK -0.27 (earnings 0.64)
· Cash flow SEK 65.9 M (4.1)
· Order backlog SEK 1,185.8 M (1,043.1) at the end of the period

HALF-YEAR (JANUARY-JUNE 2020)

· Order intake SEK 477.2 M (572.2)
· Net sales SEK 372.6 M (362.7)
· Operating profit SEK 40.6 M (52.0)
· Profit after tax SEK 31.3 M (39.0) and
earnings per share before/after dilution SEK 0.91 (1.14)
· Cash flow SEK 61.7 M (2.3)

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

· The RayStation® treatment planning system was selected by several leading cancer centers, including Miami Cancer Institute, Asante Three Rivers Medical Center and the Medical University of South Carolina in the US, Southern TOHOKU BNCT Research Center in Japan, the National Cancer Institute in Thailand, Oncorad Garonne (Clinique du Pont De Chaume i Montauban) in France, and Chungnam National University Hospital in South Korea.
· RaySearch and Varian Medical Systems concluded an interoperability agreement in order to connect the RayCare® oncology information system with Varian's TrueBeam® linear accelerator.
· RaySearch and TAE Life Sciences in the US initiated a collaboration regarding treatment planning in boron neutron capture therapy (BNCT) for TAE's AlphaBeam® neutron system.

· In June, RayStation 10A*, the latest version of RaySearch's treatment planning system, was released, with major performance enhancements for proton therapy, new support for ocular proton therapy planning, and improved ability to generate treatment plans using machine learning in the Plan Explorer module.
· In June, RayCare 4A*, the latest version of RaySearch's oncology information system, was released, with new functionalities including dynamic team management, scripting support and an improved patient chart.
 

UPDATE REGARDING COVID-19

· RaySearch expects that the COVID-19 pandemic will continue to have a significantly adverse effect on the company's sales and earnings for several months to come, mainly because orders may be delayed.
· Management is monitoring the situation closely and is prepared to take action if needed.
 

The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on August 26, 2020 at 7:45 a.m. CET.
 

TELECONFERENCE IN CONJUNCTION WITH THE INTERIM REPORT

CEO Johan Löf and CFO Peter Thysell will present RaySearch's interim report for January-June 2020 at a teleconference to be held in English on Wednesday, August 26, 2020 at 15:00-15:30 CET.

For login details to the teleconference, please register on:
http://emea.directeventreg.com/registration/6391624 
 

FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President and CEO    Tel: +46 8 510 530 00              E-mail: johan.lof@raysearchlabs.com
Peter Thysell, CFO                      Tel: +46 70 661 05 59              E-mail: peter.thysell@raysearchlabs.com
 

ABOUT RAYSEARCH
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to cancer centers all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing a new treatment control system, RayCommand, which is expected to be launched at the beginning of 2021. RaySearch's software is currently used by over 2,600 centers in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed for trading on Nasdaq Stockholm since 2003.
More information about RaySearch is available at www.raysearchlabs.com

* Regulatory clearance is required in some markets.

https://news.cision.com/raysearch-laboratories/r/interim-report-january-1---june-30--2020,c3181200

https://mb.cision.com/Main/1102/3181200/1297268.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English


share with twitter share with LinkedIn share with facebook
All news about RAYSEARCH LABORATORIES AB (PUBL)
10/23RAYSEARCH LABORATORIES : will present further advances in machine learning and s..
AQ
09/16RAYSEARCH LABORATORIES : Cutting-edge cancer treatment comes to Belgium with the..
AQ
08/28RAYSEARCH LABORATORIES : RayStation in clinical use at both of Spain's proton ce..
AQ
08/26RAYSEARCH LABORATORIES : Interim report January 1 - June 30, 2020
AQ
07/15RAYSEARCH LABORATORIES PUBL : and TAE Life Sciences announce agreement on RaySta..
AQ
07/09RAYSEARCH LABORATORIES PUBL : Further clinical implementation of deep learning s..
AQ
06/30RAYSEARCH LABORATORIES PUBL : Bulletin from the Annual General Meeting 2020
AQ
06/29RAYSEARCH LABORATORIES PUBL : Machine learning algorithm from RaySearch enhances..
AQ
06/29RAYSEARCH LABORATORIES PUBL : Pioneering oncology information system RayCare 4A ..
AQ
06/24RAYSEARCH LABORATORIES PUBL : Axim Nuclear & Oncology to supply RaySearch system..
AQ
More news
Financials
Sales 2020 779 M 89,1 M 89,1 M
Net income 2020 66,5 M 7,61 M 7,61 M
Net cash 2020 15,0 M 1,72 M 1,72 M
P/E ratio 2020 39,1x
Yield 2020 0,40%
Capitalization 2 585 M 296 M 296 M
EV / Sales 2020 3,30x
EV / Sales 2021 2,80x
Nbr of Employees 396
Free-Float 69,7%
Chart RAYSEARCH LABORATORIES AB (PUBL)
Duration : Period :
RaySearch Laboratories AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RAYSEARCH LABORATORIES AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 93,50 SEK
Last Close Price 75,40 SEK
Spread / Highest target 26,0%
Spread / Average Target 24,0%
Spread / Lowest Target 22,0%
EPS Revisions
Managers
NameTitle
Johan Löf President, Chief Executive Officer & Director
Lars Micael Wollung Chairman
Peter Thysell Chief Financial Officer
Kjell Eriksson Chief Research Officer
Carl Filip Bergendal Director
Sector and Competitors
1st jan.Capitalization (M$)
RAYSEARCH LABORATORIES AB (PUBL)-25.28%313
VEEVA SYSTEMS INC.111.06%44 773
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED126.11%35 297
OMNICELL, INC.2.91%3 612
SECTRA AB (PUBL)54.99%2 660
PRO MEDICUS LIMITED49.84%2 492